[Use of risk-adapted programs of treatment of Hodgkin's disease in children and adolescents].
The end results of treatment of Hodgkin's disease are evaluated. Since survival rates for patients receiving risk-adapted programs (DAL-Hd, SPBLKH-05) were higher than in control (MOPP), relevant protocols using lower drug dosage should be recommended in groups of favorable and intermediate risk.
Kuleva
S A
SA
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone